Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report released on Friday. The brokerage issued a sell rating on the stock.

A number of other brokerages have also recently issued reports on SYRS. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Trading Up 2.2 %

SYRS opened at $0.21 on Friday. The firm’s 50 day simple moving average is $0.23 and its two-hundred day simple moving average is $2.00. Syros Pharmaceuticals has a 1-year low of $0.18 and a 1-year high of $7.96.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the company earned ($1.35) EPS. As a group, sell-side analysts predict that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Syros Pharmaceuticals

In related news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 12.26% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

An institutional investor recently raised its position in Syros Pharmaceuticals stock. Exome Asset Management LLC lifted its stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 298,575 shares of the company’s stock after buying an additional 139,400 shares during the quarter. Exome Asset Management LLC owned approximately 1.11% of Syros Pharmaceuticals worth $642,000 as of its most recent SEC filing. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.